TransMedics Group, Inc.
TMDX Nasdaq
SEC CIK 1756262
Follow TransMedics
Weekly email: filings, results
Revenue, last quarter
$203M
+41.1% vs same quarter last year
Net income
$17.1M
−29.8% vs same quarter last year
EPS, diluted
$0.46
−30.3% vs same quarter last year
Operating cash flow
$36M
−48.3% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $605.5M | $190.3M |
| FY24 | $441.5M | $35.5M |
| FY23 | $241.6M | −$25M |
| FY22 | $93.5M | −$36.2M |
| FY21 | $31.4M | −$44.2M |
| FY20 | $28.4M | −$28.7M |
| FY19 | $25.8M | −$33.5M |
| FY18 | $14.7M | −$23.8M |
| FY17 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 59.9% | 17.9% | 31.4% |
| FY24 | 59.4% | 8.5% | 8% |
| FY23 | 63.8% | −11.9% | −10.3% |
| FY22 | 69.8% | −33.6% | −38.7% |
| FY21 | 67.4% | −125.6% | −140.8% |
| FY20 | 58.7% | −93% | −101.4% |
| FY19 | 53.6% | −114.5% | −129.8% |
| FY18 | 39.1% | −138.1% | −162.1% |
| FY17 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $133.6M |
| FY24 | −$80.9M |
| FY23 | −$164.9M |
| FY22 | −$57.7M |
| FY21 | −$32.4M |
| FY20 | −$30.7M |
| FY19 | −$32.5M |
| FY18 | −$26.4M |
| FY17 | - |
- TransMedics
- Healthcare median
Show the numbers
| Year | TransMedics | Healthcare median |
|---|---|---|
| FY25 | 31.4% | −30.8% |
| FY24 | 8% | −47% |
| FY23 | −10.3% | −58% |
| FY22 | −38.7% | −80.4% |
| FY21 | −140.8% | −71.9% |
| FY20 | −101.4% | −62.2% |
| FY19 | −129.8% | −46.3% |
| FY18 | −162.1% | −49.6% |
| FY17 | - | −45.9% |